{
    "Clinical Trial ID": "NCT00091832",
    "Intervention": [
        "干预一:",
        "二氧化 IV Q4W",
        "开放标签磷酸盐每4周(Q4W)通过静脉注射",
        "干预2:",
        "丹诺苏马布 30 mg Q4W",
        "Denosumab 30 mg 每 4 周通过皮下注射(Q4W)"
    ],
    "Eligibility": [
        "纳入标准:  histologically 或 cytologically 确认的乳腺腺癌",
        "至少有一個骨移"
    ],
    "Results": [
        "测量结果:",
        "从基准到第13周的激素调节尿液N-望远的百分比变化(uNTx/Cr)",
        "从基准值到第13周的尿液N-telopeptide的百分比变化,以创造素(uNTx/Cr)校正,用 ((第13周值 - 基准值) / 基准值 ) x 100计算。",
        "时间框架:基线和第13周",
        "结果一:",
        "品牌名称:Bisphosphonate IV Q4W",
        "手臂/群组描述:每4周一次(Q4W)通过静脉注射的开放标签磷酸盐",
        "分析的参与者总数: 38",
        "标准偏差(Standard deviation)",
        "衡量单位:百分比变化 -10.19 (208.84)",
        "结果二:",
        "手臂/组名称: Denosumab 30 mg Q4W",
        "手臂/群组描述:每 4 周以皮下注射 30 mg Denosumab (Q4W)",
        "分析的参与者总数:40人",
        "标准偏差(Standard deviation)",
        "衡量单位:百分比变化 -52.87 (95.14)"
    ],
    "Adverse Events": [
        "意外事件一:",
        "总数: 15/43 (34.88%)",
        "白内障 0/43 (0.00%)",
        "发烧性骨髓缩 0/43 (0.00%)",
        "发烧性中毒性 1/43 (2.33%)",
        "白血病 0/43 (0.00%)",
        "内分裂症 1/43 (2.33%)",
        "甲状腺炎 0/43 (0.00%)",
        "焦虑症 0/43 (0.00%)",
        "心脏干燥剂 0/43 (0.00%)",
        "心脏呼吸停止 0/43 (0.00%)",
        "心肺衰竭 1/43 (2.33%)",
        "心脏排泄 0/43 (0.00%)",
        "不利事件二:",
        "总数: 11/42 (26.19%)",
        "贫血 1/42 (2.38%)",
        "发烧性骨髓缩 1/42 (2.38%)",
        "发烧性中微波尼亚 0/42 (0.00%)",
        "白血病 0/42 (0.00%)",
        "中性衰竭 0/42 (0.00%)",
        "甲状腺炎 0/42 (0.00%)",
        "焦虑症 1/42 (2.38%)",
        "心脏干燥剂 0/42 (0.00%)",
        "心脏呼吸停止 0/42 (0.00%)",
        "心肺衰竭 0/42 (0.00%)",
        "心脏输出 1/42 (2.38%)"
    ]
}